GlassScriptPhysician profile
Gerold N Sibanda
NPI 1063520591
$4,145.26
in general payments reported to CMS, 2019-2025
29 companies · $883 in 2025
The $883 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $218 · 2022: $168 · 2023: $819 · 2024: $969 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $773.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $650.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $494.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $476.48 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $294.29 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Dexcom, INC. | $293.29 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $264.76 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.62 | 2020-2023 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $139.94 | 2019-2020 | |
| Astellas Pharma US INC | $138.26 | 2019-2024 | Veozah |
| Abbott Laboratories | $66.40 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $51.27 | 2023-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $38.68 | 2019-2023 | Yupelri |
| Shield Therapeutics INC | $38.17 | 2023-2024 | Accrufer |
| Antares Pharma, INC. | $37.07 | 2025 | Xyosted |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.04 | 2019-2020 | |
| Axsome Therapeutics, INC. | $28.34 | 2024 | Sunosi |
| Corcept Therapeutics | $21.92 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $18.73 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.26 | 2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $16.75 | 2019 | |
| Sumitomo Pharma America, INC. | $16.06 | 2025 | Gemtesa |
| Atland Pharmaceuticals, LLC | $15.67 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Genentech USA, INC. | $14.86 | 2019 | |
| Hikma Pharmaceuticals USA | $14.30 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.16 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $13.07 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $12.31 | 2019 | |
| Allergan, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerold Sibanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.